Article
Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.
The oncologist - 1 Jan 2013
Goldberg Sarah B, Oxnard Geoffrey R, Digumarthy Subba, Muzikansky Alona, Jackman David M, Lennes Inga T, Sequist Lecia V
Abstract excerpt
Epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer has an oncogene-addicted biology that confers sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Published data suggest that EGFR addiction persists after development of TKI acquired resistance, leading many clinicians to continue TKI with subsequent chemotherapy; however, this strategy has not been formally evaluated. Methods. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.